Analyst Price Target is $105.00
▲ +8.12% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for QuidelOrtho in the last 3 months. The average price target is $105.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 8.12% upside from the last price of $97.11.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in QuidelOrtho. This Buy consensus rating has held steady for over two years.
QuidelOrtho Corporation provides various in vitro diagnostics products worldwide. The company's product portfolio covers a range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and clinical and at-home products to detect COVID-19. It provides visually-read lateral flow products in infectious disease and reproductive health; direct fluorescent antibodies in infectious disease and virology; micro-titer production with a focus on bone and complement pathway markets; fluorescent immunoassay products; molecular diagnostic products comprising Savanna, an integrated molecular diagnostic system; immunodiagnostics, clinical chemistry, and integrated testing systems to serve diagnostic labs of all sizes; immunodiagnostic donor screening systems and services that drive blood safety; pre-transfusion testing that automates blood bank workload with software to standardize operations, simplify tasks, and improve productivity; and Ortho Care services and informatics products. The company was founded in 1979 and is headquartered in San Diego, California.
Read More